ストックスクリーナーアプリを入手
39.46
6.48%
2.40
プレマーケット:
40.00
0.54
+1.37%
Apogee Therapeutics Inc (APGE) 最新ニュース
(APGE) Investment Report - Stock Traders Daily
Apogee Therapeutics (NASDAQ:APGE) Stock Price Down 4.6%Should You Sell? - MarketBeat
Comparing Apogee Therapeutics (NASDAQ:APGE) and BioCardia (NASDAQ:BCDA) - Defense World
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $89.71 - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 15,000 Shares - MarketBeat
CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus.com
Apogee Therapeutics CEO sells shares worth $732,692 By Investing.com - Investing.com Australia
Apogee Therapeutics CEO sells shares worth $732,692 - Investing.com India
Apogee Therapeutics (NASDAQ:APGE) Shares Down 9.1%What's Next? - MarketBeat
Trend Tracker for (APGE) - Stock Traders Daily
Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Principal Financial Group Inc. Sells 2,925 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics chief medical officer sells shares worth $191,739 By Investing.com - Investing.com Australia
Carl Dambkowski Sells 4,085 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock - MarketBeat
Apogee Therapeutics chief medical officer sells shares worth $191,739 - Investing.com India
Passage Bio (NASDAQ:PASG) & Apogee Therapeutics (NASDAQ:APGE) Head-To-Head Contrast - Defense World
Learn to Evaluate (APGE) using the Charts - Stock Traders Daily
This Apogee Therapeutics Insider Increased Their Holding In The Last Year - Yahoo Finance
Geode Capital Management LLC Increases Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics (NASDAQ:APGE) Stock Price Down 3.2%What's Next? - MarketBeat
Franklin Resources Inc. Has $48.05 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Trading Up 6.1% After Insider Buying Activity - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Short Interest Up 11.2% in November - Defense World
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Price Target at $83.88 - Defense World
Apogee Therapeutics (NASDAQ:APGE) Trading 6.1% Higher Following Insider Buying Activity - MarketBeat
State Street Corp Cuts Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up Following Insider Buying Activity - Defense World
Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up on Insider Buying Activity - MarketBeat
Insider Buying: Mark Mckenna Acquires 20,000 Shares of Apogee Th - GuruFocus.com
Apogee Therapeutics, Inc. (NASDAQ:APGE) Director Mark C. Mckenna Acquires 20,000 Shares of Stock - MarketBeat
Apogee Therapeutics director Mark McKenna acquires $990,775 in stock By Investing.com - Investing.com Canada
Apogee Therapeutics : Statement of Changes in Beneficial Ownership (Form 4) - Marketscreener.com
Apogee Therapeutics director Mark McKenna acquires $990,775 in stock - Investing.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.89 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Sees Large Increase in Short Interest - MarketBeat
Barclays PLC Grows Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics’ (APGE) “Buy” Rating Reiterated at Guggenheim - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 4,540 Shares - MarketBeat
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $83.88 - MarketBeat
Apogee Therapeutics' chief medical officer sells $221,362 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics' chief medical officer sells $221,362 in stock - Investing.com
Financial Survey: Apogee Therapeutics (NASDAQ:APGE) versus DBV Technologies (NASDAQ:DBVT) - Defense World
Guggenheim maintains buy on Apogee stock amid trial failures - Investing.com
Apogee Therapeutics Initiates Dosing of APG333 in Phase 1 Clinical Trial - Defense World
Apogee Therapeutics, Inc. Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions - Marketscreener.com
Apogee Therapeutics Advances Clinical Trials for APG333 - TipRanks
Apogee Therapeutics Announces First Participants Dosed in - GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its - The Bakersfield Californian
4.81%
大文字化:
|
ボリューム (24 時間):